Karen Yeo, MD
Family Medicine · Glendale, CANPI 1316094543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Vanda Pharmaceuticals Inc. at 41.5% of the total. Reporting peaked in 2022 at $194 and has fallen 73.2% since, to $52 in 2025.
Across 20 payments — averaging $24.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$204
- AbbVie$109
- Novo Nordisk$53
- Sanofi Pasteur Inc.$46
- Radius Health, Inc.$40
- Lilly USA, LLC$21
- plus $18 from 1 others
What the payments were for
- Food & beverage$492100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $204 |
| AbbVie | 4 | $109 |
| Novo Nordisk | 3 | $53 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Radius Health, Inc. | 2 | $40 |
| Lilly USA, LLC | 1 | $21 |
| GSK | 1 | $18 |
How this compares
$492 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 177 | $1,213 |
| Levothyroxine Sodium | 82 | $771 |
| Rosuvastatin Calcium | 47 | $630 |
| Losartan Potassium | 96 | $570 |
| FenofibrateFenofibrate Nanocrystallized | 15 | $568 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $516 |
| Alendronate Sodium | 41 | $404 |
| Benazepril Hcl | 27 | $326 |
| Metformin Hcl | 58 | $301 |
| Lisinopril | 63 | $264 |
| Omeprazole | 29 | $263 |
| Amlodipine Besylate | 85 | $262 |
| Pravastatin Sodium | 11 | $246 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 11 | $189 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $177 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Glendale
- Narineh ArutyounianGlendale$76K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.